FDA Warns Novo Nordisk Over Unreported Ozempic Safety Incidents

2026-03-11 companies

Plainsboro, Wednesday, 11 March 2026.
The FDA warned Novo Nordisk over systemic failures to report severe Ozempic side effects, including three patient deaths, highlighting intensified regulatory scrutiny on the lucrative weight-loss market.

Systemic Failures in Pharmacovigilance

The regulatory action stems from an extensive inspection conducted by the FDA between January 13 and February 7, 2025, at Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey [1][6]. Following the initial inspection, the agency issued a Form 483 outlining preliminary concerns, which ultimately escalated into a formal warning letter dated March 5, 2026 [1][2][5]. The FDA identified what it described as systemic failures in the company’s pharmacovigilance program, particularly concerning Postmarketing Adverse Drug Experience (PADE) reporting requirements [6]. Investigators found that Novo Nordisk implemented an internal policy requiring consent from reporters before following up on adverse events—a practice not mandated by federal regulations [6]. This procedural bottleneck led to severe cases going uninvestigated and unreported [6].

Unreported Fatalities and Suicidal Ideation

The consequences of these reporting delays are significant. The FDA’s March 5 letter cited three patient deaths among individuals taking semaglutide that were not reported within the required regulatory timeframe [2][3]. One notable instance involved an unreported fatality that was dismissed simply because staff failed to capture a patient identifier [6]. Another involved a patient who died by suicide, which the company failed to investigate or report properly [2][3]. Additionally, a separate report of suicidal ideation received in December 2024 was left unreviewed until February 2025, and only then because FDA inspectors intervened during their site visit [6].

Portfolio-Wide Impact and Market Reaction

The scope of the agency’s reprimand extends beyond just the GLP-1 weight-loss franchise. Based on the inspection findings and the company’s subsequent written responses, the FDA stated it has “serious concerns about the scope and impact of these violations on your entire product portfolio” [1][5]. This sweeping language underscores the severity of the regulatory breach. Following the news of the warning letter, shares of Novo Nordisk (NYSE: NVO) experienced a minor setback, dropping by 3 percent [7].

The Path Forward for Novo Nordisk

To rectify the systemic failures, Novo Nordisk is undertaking a massive internal overhaul. The company is revising its standard operating procedures, transitioning the intake of safety cases to in-house professionals, and establishing dedicated vendor management teams [6]. In a move that highlights the depth of the historical audit required, the drugmaker is reviewing reporting deviations dating all the way back to June 2017 [6]. Anna Windle, head of clinical development, medical, and regulatory affairs for Novo Nordisk U.S., stated that the company takes PADE requirements seriously and is confident it will resolve the matters to the FDA’s “full satisfaction” [1][3][6]. The FDA has given the company a two-week deadline from the letter’s issuance to detail future preventative measures [2].

Sources

Novo Nordisk FDA warning